A promoter methylation pattern in the N-methyl-D-aspartate receptor 2B gene predicts poor prognosis in esophageal squamous cell carcinoma

Sook Kim Myoung, Keishi Yamashita, Kwang Chae Young, Yutaka Tokumaru, Xiaofei Chang, Marianna Zahurak, Motonobu Osada, Hannah Lui Park, Alice Chuang, Joseph A. Califano, David Sidransky

Research output: Contribution to journalArticle

Abstract

Purpose: To investigate whether the promoter methylation pattern in N-methyl-D-aspartate receptor 2B (NMDAR2B) is correlated with clinical features of human esophageal squamous cell carcinoma (ESCC), the methylation status of the gene was examined at three different sites (P1, P2, and P3) where two CpG islands reside within 1kb upstream of the transcription start site. Experimental Design: Three independent modalities for methylation analysis (bisulfite sequencing, combined bisulfite restriction analysis, and TaqMan methylation-specific PCR) were done to analyze total 67 ESCC tissues that included 43 primary tumors with well-characterized clinicopathologic variables including patient outcome. Results: Using an optimized cutoff value based on quantitative methylation-specific PCR, we found that patients with higher NMDAR2B methylation ratio in the proximal region (P1) showed a worse 5-year disease-specific survival rate than those without NMDAR2B methylation (P <0.006). A significant correlation was also seen between NMDAR2B promoter methylation and the presence of vascular permeation (P = 0.03). Conclusion: NMDAR2B promoter methylation could be a clinically applicable marker in ESCC.

Original languageEnglish (US)
Pages (from-to)6658-6665
Number of pages8
JournalClinical Cancer Research
Volume13
Issue number22
DOIs
StatePublished - Nov 15 2007

Fingerprint

N-Methyl-D-Aspartate Receptors
Methylation
Genes
Esophageal Squamous Cell Carcinoma
Polymerase Chain Reaction
CpG Islands
Transcription Initiation Site
Blood Vessels
Research Design
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A promoter methylation pattern in the N-methyl-D-aspartate receptor 2B gene predicts poor prognosis in esophageal squamous cell carcinoma. / Myoung, Sook Kim; Yamashita, Keishi; Young, Kwang Chae; Tokumaru, Yutaka; Chang, Xiaofei; Zahurak, Marianna; Osada, Motonobu; Park, Hannah Lui; Chuang, Alice; Califano, Joseph A.; Sidransky, David.

In: Clinical Cancer Research, Vol. 13, No. 22, 15.11.2007, p. 6658-6665.

Research output: Contribution to journalArticle

Myoung, SK, Yamashita, K, Young, KC, Tokumaru, Y, Chang, X, Zahurak, M, Osada, M, Park, HL, Chuang, A, Califano, JA & Sidransky, D 2007, 'A promoter methylation pattern in the N-methyl-D-aspartate receptor 2B gene predicts poor prognosis in esophageal squamous cell carcinoma', Clinical Cancer Research, vol. 13, no. 22, pp. 6658-6665. https://doi.org/10.1158/1078-0432.CCR-07-1178
Myoung, Sook Kim ; Yamashita, Keishi ; Young, Kwang Chae ; Tokumaru, Yutaka ; Chang, Xiaofei ; Zahurak, Marianna ; Osada, Motonobu ; Park, Hannah Lui ; Chuang, Alice ; Califano, Joseph A. ; Sidransky, David. / A promoter methylation pattern in the N-methyl-D-aspartate receptor 2B gene predicts poor prognosis in esophageal squamous cell carcinoma. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 22. pp. 6658-6665.
@article{f5cbcb3158b5413fb0d36e8d858fc913,
title = "A promoter methylation pattern in the N-methyl-D-aspartate receptor 2B gene predicts poor prognosis in esophageal squamous cell carcinoma",
abstract = "Purpose: To investigate whether the promoter methylation pattern in N-methyl-D-aspartate receptor 2B (NMDAR2B) is correlated with clinical features of human esophageal squamous cell carcinoma (ESCC), the methylation status of the gene was examined at three different sites (P1, P2, and P3) where two CpG islands reside within 1kb upstream of the transcription start site. Experimental Design: Three independent modalities for methylation analysis (bisulfite sequencing, combined bisulfite restriction analysis, and TaqMan methylation-specific PCR) were done to analyze total 67 ESCC tissues that included 43 primary tumors with well-characterized clinicopathologic variables including patient outcome. Results: Using an optimized cutoff value based on quantitative methylation-specific PCR, we found that patients with higher NMDAR2B methylation ratio in the proximal region (P1) showed a worse 5-year disease-specific survival rate than those without NMDAR2B methylation (P <0.006). A significant correlation was also seen between NMDAR2B promoter methylation and the presence of vascular permeation (P = 0.03). Conclusion: NMDAR2B promoter methylation could be a clinically applicable marker in ESCC.",
author = "Myoung, {Sook Kim} and Keishi Yamashita and Young, {Kwang Chae} and Yutaka Tokumaru and Xiaofei Chang and Marianna Zahurak and Motonobu Osada and Park, {Hannah Lui} and Alice Chuang and Califano, {Joseph A.} and David Sidransky",
year = "2007",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-07-1178",
language = "English (US)",
volume = "13",
pages = "6658--6665",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - A promoter methylation pattern in the N-methyl-D-aspartate receptor 2B gene predicts poor prognosis in esophageal squamous cell carcinoma

AU - Myoung, Sook Kim

AU - Yamashita, Keishi

AU - Young, Kwang Chae

AU - Tokumaru, Yutaka

AU - Chang, Xiaofei

AU - Zahurak, Marianna

AU - Osada, Motonobu

AU - Park, Hannah Lui

AU - Chuang, Alice

AU - Califano, Joseph A.

AU - Sidransky, David

PY - 2007/11/15

Y1 - 2007/11/15

N2 - Purpose: To investigate whether the promoter methylation pattern in N-methyl-D-aspartate receptor 2B (NMDAR2B) is correlated with clinical features of human esophageal squamous cell carcinoma (ESCC), the methylation status of the gene was examined at three different sites (P1, P2, and P3) where two CpG islands reside within 1kb upstream of the transcription start site. Experimental Design: Three independent modalities for methylation analysis (bisulfite sequencing, combined bisulfite restriction analysis, and TaqMan methylation-specific PCR) were done to analyze total 67 ESCC tissues that included 43 primary tumors with well-characterized clinicopathologic variables including patient outcome. Results: Using an optimized cutoff value based on quantitative methylation-specific PCR, we found that patients with higher NMDAR2B methylation ratio in the proximal region (P1) showed a worse 5-year disease-specific survival rate than those without NMDAR2B methylation (P <0.006). A significant correlation was also seen between NMDAR2B promoter methylation and the presence of vascular permeation (P = 0.03). Conclusion: NMDAR2B promoter methylation could be a clinically applicable marker in ESCC.

AB - Purpose: To investigate whether the promoter methylation pattern in N-methyl-D-aspartate receptor 2B (NMDAR2B) is correlated with clinical features of human esophageal squamous cell carcinoma (ESCC), the methylation status of the gene was examined at three different sites (P1, P2, and P3) where two CpG islands reside within 1kb upstream of the transcription start site. Experimental Design: Three independent modalities for methylation analysis (bisulfite sequencing, combined bisulfite restriction analysis, and TaqMan methylation-specific PCR) were done to analyze total 67 ESCC tissues that included 43 primary tumors with well-characterized clinicopathologic variables including patient outcome. Results: Using an optimized cutoff value based on quantitative methylation-specific PCR, we found that patients with higher NMDAR2B methylation ratio in the proximal region (P1) showed a worse 5-year disease-specific survival rate than those without NMDAR2B methylation (P <0.006). A significant correlation was also seen between NMDAR2B promoter methylation and the presence of vascular permeation (P = 0.03). Conclusion: NMDAR2B promoter methylation could be a clinically applicable marker in ESCC.

UR - http://www.scopus.com/inward/record.url?scp=36749032648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749032648&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-1178

DO - 10.1158/1078-0432.CCR-07-1178

M3 - Article

VL - 13

SP - 6658

EP - 6665

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -